This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent ovarian cancer.
Willingness to sign a written informed consent document .
Female, age ≥18 yrs and ≤70 yrs.
Histological or cytological confirmation of epithelial ovarian cancer, carcinoma tube, or primary peritoneal carcinoma.
Platinum refractory: progression during the first platinum-based treatment or within 4 weeks after the first platinum-based primary therapy;
Patients received vascular endothelial growth factor(VEGF)/vascular endothelial growth factor receptor(VEGFR) inhibitor, like Apatinib, Anlotinib, Fruquintinib, Bevacizumab, etc., or Aurora kinase inhibitors.
Patients received weekly paclitaxel therapy.
Has known allegies to Chiauranib, paclitaxel or any of the excipients.
Biological therapy, immunotherapy, hormonal therapy within 28 days prior to the first dose of study drug.